By a News Reporter-Staff News Editor at Pharma Business Week — According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission (SEC) filing by Zoetis Inc. (Form 11-K) was posted on June 27, 2014.
The SIC code for this company is 2834, Pharmaceutical Preparations.
There were 2 documents filed with this form. The SEC file number is 0001555280-14-000228.
The contact information for this company is 100 CAMPUS DRIVE, FLORHAM PARK NJ 07932, 973-822-7000.
Our editors provided additional information about Form 11-K: This form is a special annual report for employee stock purchase, savings, and similar plans, interests in which constitute securities registered under the 1933 Act. The Form 11-K annual report is required in addition to any other annual report of the issuer of the securities (e.g., a company’s annual report to all shareholders or Form 10-K).
A U.S. Securities and Exchange Commission filing is a formal document or financial statement submitted to the SEC by publicly-traded companies.
For additional information on this SEC filing see: http://www.sec.gov/Archives/edgar/data/1555280/0001555280-14-000228-index.html.
Keywords for this news article include: Pharmaceutical Preparations, SEC Filing, Zoetis Inc.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC
Zoetis Inc. Files SEC Form 11-K, Annual Report of Employee Stock Purchase, Savings And Similar Plans (Jun. 27, 2014)
By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission
- 1 min Read
- 07.9.2014
I’m pro-renewable energy. But I’m against worshiping any technology and blindly glossing over its drawbacks.
Thanks to the leap AI’s made this past year, you can now clone any voice from a 30-second clip.
Alnylam’s promising research interests include genetic medicines, cardio-metabolic diseases, hepatic infectious diseases and more.
Gold investors, once optimistic, now exhibit caution and are often ’frozen.’
AT&T has two significant growth areas in front of them, but can they capture the market’s attention and position themselves as a leader.
Perhaps this is naive, but I hope the worst we have to deal with is a resurrection of a lost species called bond vigilantes.
